文献速递血栓与止血

血友病合并丙型肝炎病毒感染者的肝病结局预测因素

Predictors of liver disease outcomes in individuals with hemophilia and HCV infection.
PubMed 文献 · Blood Adv · 2024-01-01

这项回顾性队列研究纳入121例血友病合并HCV感染的男性患者,分析终末期肝病(ESLD)和肝细胞癌(HCC)的发生率及预测因素。平均HCV病程54年,ESLD发生24例(19.8%),HCC发生7例(5.8%);血小板<100×10³/μL和HIV感染是ESLD的主要危险因素,ESLD是HCC的主要预测因素,ESLD也是首要死因。

要点

  • 血小板<100×10³/μL(OR 6.009)和HIV感染(OR 3.883)是ESLD的主要危险因素。
  • ESLD(OR 11.476)和血小板<100 000/μL(OR 6.159)是HCC的主要预测因素。
  • 接受抗病毒治疗的患者无一发生ESLD(P = .001),ESLD仍是首要死因(11例,32.3%)。

核心结论

  • 对血友病男性患者,慢性HCV感染的后遗症显著;ESLD的主要危险因素为血小板<100 000/μL和HIV感染,尽管接受抗病毒治疗,ESLD仍是HCC最重要的预测因素和首要死因。

研究设计与样本

  • 回顾性队列研究,纳入在美国宾夕法尼亚州西部血友病中心接受诊治的121例血友病合并HCV感染的男性患者。
  • 采用Fisher精确检验分析ESLD和HCC的预测因素,采用Kaplan-Meier时间-事件分析和Cox比例风险回归分析HCV相关结局。

主要发现

  • HCV平均病程54年(范围36-80年),ESLD发生24例(19.8%),发生率0.365/100人年;HCC发生7例(5.8%),发生率0.106/100人年。
  • 抗病毒治疗可及时有46例(38.0%)存活,全部接受了治疗;总体31例(25.6%)为HIV阳性。
  • 主要死因:ESLD 11例(32.3%)、出血9例(26.5%)、HCC 6例(17.6%)。
  • ESLD的主要危险因素包括血小板<100×10³/μL(OR 6.009,P = .012)和HIV感染(OR 3.883,P = .001)。
  • HCC的主要预测因素为ESLD(OR 11.476,P = .003)和血小板<100 000/μL(OR 6.159,P = .014);接受抗病毒治疗的患者无一发生ESLD(P = .001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia is an X-linked congenital bleeding disorder for which factor replacement is life-saving but complicated by the sequelae of chronic hepatitis C virus (HCV) infection acquired decades ago. Although antiviral therapy clears HCV and reduces end-stage liver disease (ESLD), it may not reverse cirrhosis or prevent hepatocellular cancer (HCC). This was a retrospective cohort study of 121 men with hemophilia and HCV infection cared for at the Hemophilia Center of Western Pennsylvania to determine the incidence and predictors of ESLD and HCC. ESLD and HCC predictors were analyzed using Fisher exact test, and HCV-associated outcomes by Kaplan-Meier time-to-event and Cox proportional hazards regression analyses. At a mean 54 years (36-80) duration of HCV, ESLD occurred in 24 (19.8%), 0.365 per 100 person-years (py); and HCC in 7 (5.8%), 0.106 per 100 py. All 46 (38.0%) alive when HCV antiviral therapy became available, received it. Overall, 31 (25.6%) were HIV+. The leading causes of death were ESLD in 11 (32.3%), bleeding in 9 (26.5%), and HCC in 6 (17.6%). Major risk factors for ESLD included platelets <100 × 103/μL (odds ratio [OR], 6.009; P = .012) and HIV infection (OR, 3.883; P = .001). The major predictors of HCC were ESLD (OR, 11.476; P = .003) and platelets <100 000/μL (OR, 6.159; P = .014). No antiviral-treated patient developed ESLD, P = .001. For men with hemophilia, the sequelae of chronic HCV infection were significant. The major risk factors for ESLD were platelets <100 000/μL and HIV infection. Despite antiviral therapy, ESLD is the most significant predictor of HCC, and ESLD is the leading cause of death.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Christodoulou I, Rothenberger S, Ragni MV, et al. Predictors of liver disease outcomes in individuals with hemophilia and HCV infection. Blood Adv. 2024. PMID: 39361728. doi:10.1182/bloodadvances.2024014350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。